《LANCET,2月4日,Baricitinib as potential treatment for 2019-nCoV acute respiratory disease》

  • 来源专题:COVID-19科研动态监测
  • 编译者: zhangzx
  • 发布时间:2020-02-05
  • BenevolentAI's knowledge graph is a large repository of structured medical information, including numerous connections extracted from scientific literature by machine learning.2 Together with customisations bespoke to 2019-nCoV, we used BenevolentAI to search for approved drugs that could help, focusing on those that might block the viral infection process. We identified baricitinib, which is predicted to reduce the ability of the virus to infect lung cells.

  • 原文来源:https://www.sciencedirect.com/science/article/pii/S0140673620303044
相关报告
  • 《LANCET,2月7日,Pandemic potential of 2019-nCoV》

    • 来源专题:COVID-19科研动态监测
    • 编译者:zhangmin
    • 发布时间:2020-02-09
    • Pandemic potential of 2019-nCoV Robin Thompson Published:February 07, 2020DOI:https://doi.org/10.1016/S1473-3099(20)30068-2 An important determinant of whether or not 2019 novel coronavirus (2019-nCoV) will ultimately cause a global pandemic is its ability to become established upon its importation to a new country. Cases of 2019-nCoV infection have so far been reported in 24 countries, yet little human-to-human transmission outside of China has occurred.
  • 《LANCET,4月3日,Baricitinib for COVID-19: a suitable treatment?》

    • 来源专题:COVID-19科研动态监测
    • 编译者:xuwenwhlib
    • 发布时间:2020-04-04
    • Baricitinib for COVID-19: a suitable treatment? Ennio G Favalli,Martina Biggioggero,Gabriella Maioli,Roberto Caporali Published:April 03, 2020DOI:https://doi.org/10.1016/S1473-3099(20)30262-0 As rheumatologists used to treating rheumatoid arthritis with Janus kinase (JAK) inhibitors and working in an area (Lombardy, Italy) with a high incidence of coronavirus disease 2019 (COVID-19), we read with great interest the Comment in The Lancet Infectious Diseases by Justin Stebbing and colleagues1 about the potential use of baricitinib for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The described mechanism affecting viral endocytosis mediated by two members of the numb-associated kinase family is one of the many unfamiliar effects of a relatively recent drug class, the real safety profile of which still remains to be definitively clarified. Undoubtedly, the fact that baricitinib can provide this antiviral effect at the approved dose for rheumatoid arthritis therapy is an undeniable advantage over other potential inhibitors of the same pathway.